Overview / Abstract: |
Much has been written recently about the need for genetic testing and biomarkers to identify specific targets within cancers, recognizing that there are many subclones and individual differences within the malignancies that arise in patients, even in those with morphologically similar cancers. Another important aspect of cancer treatment is the need to optimize the dose and schedule of administered therapies. |
Expiration |
Feb 13, 2019 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
AACME - 0.75 AMA PRA Category 1 Credit TM, ACPE - .75 hours (0.075 CEUs), ANCC - is 0.8 contact hours, APRN - 0.3 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses. |
Accreditation |
AACME, ACPE, ANCC, APRN |
Presenters / Authors / Faculty |
Joseph R. Bertino, MD |
Activity Specialities / Related Topics |
Oncology / Cancer / Radiation Therapy, Hematology |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com. |
Keywords / Search Terms |
Rockpointe Free CME, CME, Oncology, Hematology, RN, NP, APN, Registered Nurse, Nurse Practitioner, Advanced Practice Nurse, Physician, Pharmacist, Pharmacology Free CE CME |